350 related articles for article (PubMed ID: 35931925)
1. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
[TBL] [Abstract][Full Text] [Related]
3. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
Johnston MS; Galan A; Watsky KL; Little AJ
JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
[TBL] [Abstract][Full Text] [Related]
4. Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
Santi Laurini G; Montanaro N; Broccoli M; Bonaldo G; Motola D
Vaccine; 2023 May; 41(18):2879-2886. PubMed ID: 37024412
[TBL] [Abstract][Full Text] [Related]
5. From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community.
Joyce MC; Mountjoy NJ; Johnson JA; Newman JT; Bandy DL; Atalla NA; Singh A; McElroy D
BMC Public Health; 2022 Dec; 22(1):2351. PubMed ID: 36517842
[TBL] [Abstract][Full Text] [Related]
6. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
[TBL] [Abstract][Full Text] [Related]
8. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Jan; 41(2):460-466. PubMed ID: 36481108
[TBL] [Abstract][Full Text] [Related]
9. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
10. Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System.
Zhao H; Souders C; Carmel M; Anger JT
Urology; 2021 Jul; 153():11-13. PubMed ID: 33864857
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
12. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
[TBL] [Abstract][Full Text] [Related]
14. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
[TBL] [Abstract][Full Text] [Related]
15. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
Sandhu S; Bhatnagar A; Kumar H; Dixit PK; Paliwal G; Suhag DK; Patil C; Mitra D
Dermatol Ther; 2021 Nov; 34(6):e15141. PubMed ID: 34546608
[TBL] [Abstract][Full Text] [Related]
16. Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine rollout in a multi-site healthcare system.
Al-Obaydi S; Hennrikus E; Mohammad N; Lehman EB; Thakur A; Al-Shaikhly T
PLoS One; 2022; 17(8):e0272691. PubMed ID: 35930586
[TBL] [Abstract][Full Text] [Related]
17. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
Moro PL; Olson CK; Zhang B; Marquez P; Strid P
Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
[TBL] [Abstract][Full Text] [Related]
18. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
Yasmin F; Najeeb H; Naeem U; Moeed A; Atif AR; Asghar MS; Nimri N; Saleem M; Bandyopadhyay D; Krittanawong C; Fadelallah Eljack MM; Tahir MJ; Waqar F
Immun Inflamm Dis; 2023 Mar; 11(3):e807. PubMed ID: 36988252
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
[TBL] [Abstract][Full Text] [Related]
20. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
